First, the non-steroidal selective mineralocorticoid receptor antagonist (MRA), finerenone [31], has demonstrated clinical benefits in CKD patients with type 2 diabetes, possibly through its direct anti-fibrotic effects. Here, NR3C2 is linked to chronic kidney disease.